The Holden Comprehensive Cancer Center (HCCC) Oncology Registry is committed to collecting and providing information on all cancer patients diagnosed and/or treated at the University of Iowa Hospitals and Clinics.

The UI Hospitals and Clinics is a National Cancer Institute (NCI) designated Comprehensive Cancer Center which includes a wide range of multidisciplinary cancer care programs. UI Hospitals and Clinics is also approved by the American College of Surgeons Commission on Cancer (ACoS/CoC) as an Approved Cancer Program. UI Hospitals and Clinics was surveyed by the ACoS CoC in the last quarter of 2004 and obtained a 3yr approval (highest) with commendations. The most recent ACoS CoC survey was held the last quarter 2007 under the new standards specific for NCI facilities. While official results are pending – we anticipate another full 3-year approval (highest) with commendations.

UI Hospitals and Clinics has data available from 1938 to present for medical staff to analyze and utilize to enhance and improve patient care. Data are abstracted from the patient’s medical record within 6 months of initial diagnosis and include such information as: demographics, stage of disease (at diagnosis), Collaborative Staging, first course treatment information, cancer status and vital status; all as required by the ACoS CoC. Collaborative Staging is a carefully selected set of data items that describe how far a cancer has spread at the time of diagnosis

UI Hospitals and Clinics accessions all inpatients and outpatients with malignant disease and all benign and borderline primary tumors of the brain and central nervous system (CNS) who are initially diagnosed and/or treated at UI Hospitals and Clinics [analytic] and for patients that present with persistent, recurrent and/or metastatic disease that receive treatment at UI Hospitals and Clinics; included are patients that are diagnosed at autopsy. [non-analytic]. All data represented in this report include only analytic cases, unless otherwise specified.

Annual follow-up of patients is one of the important functions of the Oncology Registry. Follow-up is conducted for the lifetime of the patient. Most recent UI Hospitals and Clinics calculations reveal 99% success rate on all cases diagnosed within the past 5 years and a 99% success rate for patients diagnosed since reference date. The rate required by the ACoS CoC is 90% and 80% respectively. UI Hospitals and Clinics has historically surpassed these ACoS CoC requirements.

Follow-up is automatically collected on all patients (both analytic and non-analytic) who return to the UI Hospitals and Clinics.  UI Hospitals and Clinics sends out follow-up questionnaires to all patients, family and/or physician who have not returned to the UI Hospitals and Clinics in the past year making telephone contacts as necessary.

The HCCC submits data annually to two National Cancer Databases; 1) -- the National Cancer Institute Surveillance, Epidemiology and End Results (NCI SEER) via the Iowa Cancer Registry and 2) -- The American College of Surgeons National Cancer Database (NCDB). State laws require reporting of cancer.

The HCCC Activity Report will focus on three of our five leading analytic sites of cancer for this past year; accounting for 41% of the total analytic cases seen at the UI Hospitals and Clinics this past year. The leading 5 sites are: Brain/CNS, Lung, Prostate, Breast, and Endometrium.

• Introduction
• Faculty Comments
• Cancer Information Service
• Highlights
• Brain
• Lung
• Prostate
• Registry Staff
• Research Articles
• Calendar Year Report (in pdf format)